EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC 4.0

Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis

Emma Guttman-Yassky iD, Paola Facheris iD, Pedro Jesus Gomez-Arias, Ester Del Duca, Joel Correa Da Rosa, Stephan Weidinger, Robert Bissonnette, April W Armstrong, Julien Seneschal, Kilian Eyerich iD, Yeriel D Estrada, Swaroop N Bose und 7 weitere

Allergy · 2024-05 · 79 (5) · 1258-1270

DOI: 10.1111/all.15969 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Allergy, online erschienen am 18.12.2023. Verfasst von Emma Guttman-Yassky und 18 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai Medical Center, New York, New York, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Biomarkers, Skin, Sulfonamides. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer Inc., New York, NY, USA, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This is the first report on the effects of abrocitinib, a Janus kinase 1–selective inhibitor, on the expression of skin biomarkers in patients with moderate‐to‐severe atopic dermatitis (AD).

Methods

JADE MOA (NCT03915496) was a double‐blind Phase 2a trial. Adults were randomly assigned 1:1:1 to receive monotherapy with once‐daily abrocitinib 200 mg, abrocitinib 100 mg, or placebo for 12 weeks. The primary endpoint was change from baseline in markers of inflammation (matrix metalloproteinase [MMP]‐12), epidermal hyperplasia (keratin‐16 [KRT16]), T‐helper 2 (Th2) immune response (C‐C motif chemokine ligand [CCL]17, CCL18, and CCL26), and Th22 immune response (S100 calcium binding protein A8, A9, and A12 [S100A8, S100A9, and S100A12]) in skin through 12 weeks.

Results

A total of 46 patients received abrocitinib 200 mg ( n = 14), abrocitinib 100 mg ( n = 16), or placebo ( n = 16). Abrocitinib improved AD clinical signs and reduced itch. Gene expression of MMP‐12 , KRT16 , S100A8 , S100A9 , and S100A12 was significantly decreased from baseline with abrocitinib 200 mg (at Weeks 2, 4, and 12) and abrocitinib 100 mg (at Weeks 4 and 12) in a dose‐dependent manner. Abrocitinib 200 mg resulted in significant decreases from baseline in CCL17 expression at Week 12 and CCL18 expression at Weeks 2, 4, and 12; no significant decreases were observed for CCL26 .

Conclusions

Alongside improvements in clinical signs and symptoms of AD, 12 weeks of abrocitinib treatment resulted in downregulation of genes associated with inflammation, epidermal hyperplasia, and Th2 and Th22 immune responses in the skin of patients with moderate‐to‐severe AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicBiomarkersSkinSulfonamidesSeverity of Illness IndexHumansFemaleMaleAdultPyrimidinesMiddle AgedTreatment OutcomeDouble-Blind MethodYoung Adult

Stichwörter der Autor:innen

atopic dermatitisbiomarkersdermatology

Substanzen

BiomarkersabrocitinibSulfonamidesPyrimidines

Autor:innen und Institutionen

  • Icahn School of Medicine at Mount Sinai Medical Center, New York, New York, USA.
  • University Hospital Schleswig-Holstein, Kiel, Germany.
  • Innovaderm Research Inc., Montreal, Quebec, Canada.
  • University of Southern California, Los Angeles, California, USA.
  • Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-André, Bordeaux, France.
  • Bordeaux University, CNRS UMR 5164, Immunoconcept, Bordeaux, France.

ORCID-Profile: Emma Guttman-Yassky, Paola Facheris, Kilian Eyerich

Förderung

  • Pfizer Inc., New York, NY, USA
  • Pfizer

Zitieren

APA

Guttman-Yassky, E., Facheris, P., Gomez-Arias, P. J., Del Duca, E., Da Rosa, J. C., Weidinger, S., Bissonnette, R., Armstrong, A. W., Seneschal, J., Eyerich, K., Estrada, Y. D., Bose, S. N., Xu, D., Chen, A., Tatulych, S., Güler, E., Chan, G., Page, K. M., & Kerkmann, U. (2024). Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis. Allergy, 79(5), 1258-1270. https://doi.org/10.1111/all.15969

Vancouver

Guttman-Yassky E, Facheris P, Gomez-Arias PJ, Del Duca E, Da Rosa JC, Weidinger S, et al. Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis. Allergy. 2024;79(5):1258-1270. doi:10.1111/all.15969

BibTeX
@article{GuttmanYassky2024,
  author = {Guttman-Yassky, Emma and Facheris, Paola and Gomez-Arias, Pedro Jesus and Del Duca, Ester and Da Rosa, Joel Correa and Weidinger, Stephan and Bissonnette, Robert and Armstrong, April W and Seneschal, Julien and Eyerich, Kilian and Estrada, Yeriel D and Bose, Swaroop N and Xu, Dan and Chen, Allshine and Tatulych, Svitlana and Güler, Erman and Chan, Gary and Page, Karen M and Kerkmann, Urs},
  title = {Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis},
  journal = {Allergy},
  year = {2024},
  volume = {79},
  number = {5},
  pages = {1258--1270},
  doi = {10.1111/all.15969}
}
Kostenlos starten →